Bone marrow neoplastic

Home > Bone marrow neoplastic

Bone marrow neoplastic

Last staff update: 21 December 2022

Copyright: 2001-2023, PathologyOutlines.com, Inc.

HemePath related: Jobs, Fellowships, Conferences, Cases, CME

Related chapters: Bone marrow nonneoplastic, Hematology, Lymphoma & related disorders, Lymph nodes and spleen, nonlymphoid

Editorial Board oversight: Alexa J. Siddon, M.D. (last reviewed January 2022), Genevieve M. Crane, M.D., Ph.D. (last reviewed April 2020)

Page views in 2022 (this page and chapter topics): 442,162

Page views in 2023 to date (this page and chapter topics): 43,984

Table of contents

Bone marrow - neoplastic myeloid

General:books how to do a bone marrow biopsy (procedure) (pending) WHO classification - AML

Recurrent genetic abnormalities:AML with BCR-ABL1 (pending) AML with biallelic mutation of CEBPA AML with mutated NPM1 AML with mutated RUNX1 AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with t(1;3)(p36;q21) (pending) AML (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 AML with t(6;9)(p23;q34); DEK-NUP214 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with t(9;11)(p22;q23); KMT2A-MLLT3 APL with PML-RARA

AML not otherwise specified:AML with minimal differentiation (FAB AML M0) AML without maturation (FAB AML M1) AML with maturation (FAB AML M2) AMML (FAB AML M4) AML M5 M5a M5b AML M6 AMKL M7 acute basophilic leukemia AML with pseudo-Chediak-Higashi anomaly AML hypocellular

Other AML entities defined by the WHO:acute panmyelosis with myelofibrosis AML with myelodysplasia related changes myeloid leukemia associated with Down syndrome myeloid sarcoma therapy related myeloid neoplasm (therapy related AML) transient abnormal myelopoiesis associated with Down syndrome

Other AML of clinical relevance:AML with FLT3

Myelodysplastic syndromes (MDS):WHO classification - MDS isolated del(5q) MDS prognostic scoring (pending) MDS in childhood MDS with single lineage dysplasia MDS with ring sideroblasts MDS with multilineage dysplasia MDS with excess blasts MDS unclassifiable refractory cytopenia of childhood (pending)

Myeloproliferative neoplasms (MPN):WHO classification - MPN chronic eosinophilic leukemia chronic myeloid leukemia (CML), BCR-ABL1 positive chronic neutrophilic leukemia essential thrombocythemia MPN unclassifiable polycythemia vera primary myelofibrosis

Mast cell neoplasms: cutaneous mastocytosis mast cell sarcoma (pending) systemic mastocytosis

MDS / MPN: WHO classification - MDS / MPN atypical chronic myeloid leukemia; BCR-ABL1 negative chronic myelomonocytic leukemia juvenile myelomonocytic leukemia MDS / MPN - unclassifiable MDS / MPN with ring sideroblasts and thrombocytosis

Myeloid / lymphoid neoplasms with eosinophilia and gene rearrangement: PDGFRA rearrangement PDGFRB rearrangement FGFR1 rearrangement PCM1-JAK2

Myeloid neoplasms with germline predisposition without a pre-existing disorder or organ dysfunction:AML with germline CEBPA mutation (pending) with DDX41 mutation (pending)

Myeloid neoplasms with germline predisposition and pre-existing platelet disorders: with RUNX1 mutation (pending) with ANKRD26 mutation (pending) with ETV6 mutation (pending)

Myeloid neoplasms with germline predisposition and other organ dysfunction: with bone marrow failure (pending) with GATA2 mutation with telomere biology disorders (pending) with Down syndrome (pending)

Miscellaneous: blastic plasmacytoid dendritic cell neoplasm idiopathic hypereosinophilic syndrome VEXAS (pending)

Bone marrow - plasma cell and lymphoid neoplasms

Plasma cell neoplasms:heavy chain disease MGUS-IgM MGUS-non IgM non secretory myeloma (pending) plasma cell leukemia (pending) plasma cell myeloma (multiple myeloma) plasmacytoma POEMS syndrome (osteosclerotic myeloma) TEMPI syndrome (pending)

Other:acute lymphoblastic leukemia / lymphoma cryoglobulinemia monoclonal immunoglobulin deposition diseases (pending) primary amyloidosis

B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities:t(1;19)(q23;p13.3); TCF3-PBX1 t(5;14)(q31;q32); IGH / IL3 t(9;22)(q34;q11); BCR-ABL1 t(12;21)(p13;q22); ETV6-RUNX1 t(v;11q23); KMT2A rearranged BCR-ABL1-like therapy related B ALL with hyperdiploidy with hypodiploidy with iAMP21 (pending)

NK and T cell precursor lymphoid neoplasms:early T cell precursor lymphoblastic leukemia (pending) NK lymphoblastic leukemia/lymphoma (pending) T lymphoblastic lymphoma / leukemia

Acute leukemia of ambiguous lineage: acute undifferentiated leukemia (pending) ambiguous lineage NOS mixed phenotype

Disorders from other chapters: B lymphoblastic leukemia / lymphoma crystal storing histiocytosis cutaneous mastocytosis heavy chain deposition disease light chain deposition disease

Bone marrow neoplastic stains:
Lymphoblastic initial panel: CD1a CD3 CD4 CD5 CD7 CD8 CD10 CD20 CD34 PAX5 TdT
Refining panel: CD19 CD56 CD79a CD99 CD117 CD123 cleaved Notch1 myeloid markers

Primary marrow disorder initial screening: CD34 CD61 CD71 CD117 myeloperoxidase
Refining panel: CD11c CD42b E-cadherin glycophorin iron mast cell tryptase reticulin

Myeloma initial screening: CD138 kappa lambda
Refining panel: CD3 CD19 CD20 CD56 CD117 cyclin D1 EBER Ki67
FISH: myeloma prognostic probe sets

Superpages: entire chapter images virtual slides

Index (Alphabetical table of contents)

A-E:acute basophilic leukemia acute lymphoblastic leukemia / lymphoma acute panmyelosis with myelofibrosis acute undifferentiated leukemia (pending) ambiguous lineage NOS AMKL M7 AML (megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1 AML hypocellular AML M5 AML M6 AML with BCR-ABL1 (pending) AML with biallelic mutation of CEBPA AML with FLT3 AML with germline CEBPA mutation (pending) AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM AML with maturation (FAB AML M2) AML with minimal differentiation (FAB AML M0) AML with mutated NPM1 AML with mutated RUNX1 AML with myelodysplasia related changes AML with pseudo-Chediak-Higashi anomaly AML with t(1;3)(p36;q21) (pending) AML with t(6;9)(p23;q34); DEK-NUP214 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with t(9;11)(p22;q23); KMT2A-MLLT3 AML without maturation (FAB AML M1) AMML (FAB AML M4) APL with PML-RARA atypical chronic myeloid leukemia; BCR-ABL1 negative BCR-ABL1-like blastic plasmacytoid dendritic cell neoplasm chronic eosinophilic leukemia chronic myeloid leukemia (CML), BCR-ABL1 positive chronic myelomonocytic leukemia chronic neutrophilic leukemia cryoglobulinemia cutaneous mastocytosis early T cell precursor lymphoblastic leukemia (pending) essential thrombocythemia

O-Z:PCM1-JAK2 PDGFRA rearrangement PDGFRB rearrangement plasma cell leukemia (pending) plasma cell myeloma (multiple myeloma) plasmacytoma POEMS syndrome (osteosclerotic myeloma) polycythemia vera primary amyloidosis primary myelofibrosis refractory cytopenia of childhood (pending) systemic mastocytosis T lymphoblastic lymphoma / leukemia t(12;21)(p13;q22); ETV6-RUNX1 t(1;19)(q23;p13.3); TCF3-PBX1 t(5;14)(q31;q32); IGH / IL3 t(9;22)(q34;q11); BCR-ABL1 t(v;11q23); KMT2A rearranged TEMPI syndrome (pending) therapy related B ALL therapy related myeloid neoplasm (therapy related AML) transient abnormal myelopoiesis associated with Down syndrome VEXAS (pending) WHO classification - AML WHO classification - MDS WHO classification - MDS / MPN WHO classification - MPN with ANKRD26 mutation (pending) with DDX41 mutation (pending) with ETV6 mutation (pending) with RUNX1 mutation (pending) with bone marrow failure (pending) with Down syndrome (pending) with GATA2 mutation with hyperdiploidy with hypodiploidy with iAMP21 (pending) with telomere biology disorders (pending)

Bone marrow neoplastic books

Beck: 2021

Cherry: 2021

Hsi: 2017

Hudnall: 2019

Husain: 2021

IARC: 2017

Jaffe: 2016

Kantarjian: 2016

Lanzkowsky: 2016

Naeim: 2018

Wang: 2020

Find related Pathology books: hematopathology, oncology, pediatric

Home > Bone marrow neoplastic